Computational models of melanoma. by Albrecht, Marco et al.
Albrecht et al. Theoretical Biology andMedical Modelling            (2020) 17:8 
https://doi.org/10.1186/s12976-020-00126-7
REVIEW Open Access
Computational models of melanoma
Marco Albrecht1, Philippe Lucarelli1, Dagmar Kulms2 and Thomas Sauter1*
Abstract
Genes, proteins, or cells influence each other and consequently create patterns, which can be increasingly better
observed by experimental biology and medicine. Thereby, descriptive methods of statistics and bioinformatics
sharpen and structure our perception. However, additionally considering the interconnectivity between biological
elements promises a deeper and more coherent understanding of melanoma. For instance, integrative
network-based tools and well-grounded inductive in silico research reveal disease mechanisms, stratify patients, and
support treatment individualization. This review gives an overview of different modeling techniques beyond statistics,
shows how different strategies align with the respective medical biology, and identifies possible areas of new
computational melanoma research.
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Background
Melanoma is a neoplasm of the skin and originates from
transformed melanocytes. It causes the loss of 1.6 mil-
lion disease-adjusted life-years worldwide, and the inci-
dence rate will increase in the next decades [1]. Since
the discovery of the high prevalence of mutations in b-
Raf proto-oncogene (BRAF) and NRAS protooncogene,
GTPase (NRAS) [2, 3], small-molecule inhibitors such
as dabrafenib and vemurafenib have been developed.
More recently, immunotherapies, with antibodies bind-
ing immune receptors like the cytotoxic T-lymphocyte
associated protein 4 (CTLA4) or the programmed cell
death 1 (PDCD1), have proven to be clinically effec-
tive [4]. However, many drug resistance mechanisms
occurred and represent a major problem in both tar-
geted therapy and immunotherapy [5–7]. As a result, life
expectancy remains low. The two-year survival rate is
53.5% for combined BRAF + mitogen-activated protein
kinase kinases (MAP2K) inhibitors and 63% for combined
CTLA4 + PDCD1 immunotherapy [8]. Consequently,
a deeper understanding of disease mechanisms is still
demanded.
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An approach to better understand causative relations, to
check hypothesis consistency, but also to reveal miss-
ing qualitative information is constructing evidence-based
models of these biological systems [9]. Models depict
several interconnected biological elements with a struc-
ture, which is derived from the current understanding,
and parameters, which are based on data. While many
life-scientists still rely on straight-forward relationships
between observation and insight to extend their knowl-
edge, leading scientists report that the direct link between
observation and insight seems to fade [10]. Thus, experi-
mentally proven relationships are increasingly transferred
into the language of mathematics to enhance our under-
standing of experimental findings and underlying reasons.
Cancer scientists can benefit from well-designed com-
putational models, whereby systems biologists deliver
models of cancer biochemistry, and physical oncolo-
gists provide models of tissues. Systems biology helps
understanding how biochemical pathways change during
melanoma cell proliferation, invasiveness, survival, and
drug resistance based on network structure and dynamic
behavior [11]. By contrast, physical oncology helps under-
standing how transport, growth, and deformations in tis-
sues occur and is characterized by principles of geometry
and mechanics [12, 13].
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In this review, we tried to collect all published computa-
tional models of melanoma and describe them regarding
their contribution to the field. In particular, we focus on
the interconnection of system elements or network char-
acteristics while omitting classical statistics and bioin-
formatics of melanoma. By sorting models and methods
around the topic of melanoma, we intend to support
readers in finding the most appropriate mathematical
model to address their melanoma-specific research ques-
tions. Additionally, the review shall describe potentials
for improvement, encourage readers to discover poten-
tial extensions, and create awareness ofmissingmelanoma
topics to be tackled in the next decade. However, even if
some models seem simplistic in biology, they often repre-
sent technically challenging stepping-stones for more bio-
logically meaningful models in the future. Consequently,
reviewing the currently existing models might help to
push forward the modeling and computational character-
ization of melanoma.
The review is structured as follows: Network-based
approaches are explained in “Molecular networks” and
complemented by melanoma-specific repositories. The
complex interaction between molecular players requires
network-based approaches to suggest novel key interven-
tion strategies, to stratify patients, and to individualize
patient treatment. In “Cell population models: bridging
cell culture to clinics” , the dynamic changes in cell
count of different melanoma cell types, immune cells,
and fibroblasts are modeled and complemented by stim-
ulating or inhibiting effects between cells. Such cellular
models represent another way to achieve therapy indi-
vidualization and patient stratification. “Spatial models
of melanoma” leads to geometric effects which will be
augmented by the mechanics of melanoma in “Mechan-
ical models of melanoma” . Further aspects of oxygen,
nutrient, and drug transport are presented in “Trans-
port of oxygen and drugs” sections. The confined, spa-
tial, and physiological tissue environment is relevant for
tumor growth prognosis, drug delivery, surgery, and der-
moscopic pattern recognition. All available computational
melanoma models are listed in Supplemental Table 1 and
summarized in Fig. 1.
Molecular networks
Molecular networks represent larger sets of molecules in
an interconnected manner and go beyond the statistical
significance of single features and the gene-set enrichment
analysis paradigm [14]. Network science shows how bio-
logical functions emerge from the interactions between
the components of living systems and how these emer-
gent properties enable and constrain the behavior of those
components [9]. In order to explore this rich informa-
tion source, system biology provides frameworks tailored
to each commonly known -omics data type. Melanoma-
specific -omics data can be obtained from genomic [15,
16] and proteomic studies [17] but also from the secre-
tome [18] and the metabolome, respectively [19, 20].
Because multiple -omics data are rarely integrated with a
systems-centered approach [21], the following studies and
repositories are only a starting point.
Repositories to inform network models
Published knowledge in the form of structured and cen-
tralized databases facilitates model development. Beside
general sources for system biologists [22], melanoma-
specific databases are available (Table 1). The Melanoma
Molecular Map Project (MMMP) is an open-access, par-
ticipative project that structures published knowledge
about molecules, genes, and pathways to enable trans-
lational perspectives [23]. The MelGene project pro-
vides an easily searchable database of genetic associa-
tion studies of cutaneous melanoma, as well as a meta-
analysis for many polymorphisms [24]. The MelanomaDB
database lists published genomic datasets, including clin-
ical and molecular information, and allows the cre-
ation of gene lists by merging selected studies [25].
The Melanoma Gene Database (MGDB) provides exten-
sive entries about 527 melanoma-associated genes (422
protein-coding), including epigenetic and drug-related
evidence [26]. Caution is required when using these
databases, which accumulate data from multiple sources,
sometimes in an automated manner, and are therefore
susceptible to perpetuate the biases and errors of the data
source [27].
Models of melanoma genomics
The melanoma-specific repositories contain mainly
genetic data with not yet fully identified patterns. The
mutation pattern within the genome of metastatic
melanoma can be used to find mutually exclusive gene
modules [28]. If two proteins are related in an interaction
network and their genes are mutated in a way that one
gets amplified while the other gets deleted or only one
gets modified without the other, one could presume
that this happens to intensify cancer pathways at the
protein level under given pathophysiological pressure.
Consequently, one can conclude that a protein inhibits
or activates the other in a known interaction network.
The pathophysiologic pressure on cancer protein path-
ways selects mutation patterns with survival benefits.
One analysis of The Cancer Genome Atlas (TCGA)
melanoma samples integrated somatic mutations with
copy number alterations and found concomitant dereg-
ulation of the G-protein and MAPK signaling pathways
[29]. Similarly, integrated genomic and epigenomic
analyses have been used to classify melanoma brain
metastases in different mutually exclusive molecular
subtypes [30].
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Fig. 1 Computational and experimental approaches to understand cancer. Experimental approaches span from 2D cell culture to clinical
data and are often correlated directly. Possible intermediate steps can delineate the response of cells to certain characteristics of the environment.
Cells on gel sense the rigidity of the substratum, spheroids in hanging drops can develop a necrotic core, spheroid growing in alginate capsules
reveal the growth pressure at which the capsule burst, spheroids in gel reveal the cellular response to a confined environment, spheroids in a tissue
construct shows interactions with fibroblasts and host cells in a confined environment, and organotypic constructs and histological sections
emphasize the behavior in a realistic anatomical structure. Computational models change accordingly in scale and approach. Methods are
classified counter-clockwise, beginning at the top left corner. Descriptive methods of statistics and bioinformatics focus on the identification of single
features. Often groups are compared, or the explanatory power of certain factors is investigated. Systems biologists increasingly connect different
elements, focus on network information, and study dynamic effects. The network topology in steady-state is the first step but can also be extended
to time dynamic and directed interactions. The networks might be compartmentalized to study communication across different cells, but the cells
themselves can also represent network nodes, which is common in immunological studies. If interconnections between cells, with or without ECM,
are studied and spatially distributed, on-grid and off-grid cellular automatons, vertex models, and reaction-diffusion models become relevant.
Deformed tissue structures and anatomical obstacles require the integration of mechanical information. The more the approaches move from cell
data to clinical images, the more pattern recognition becomes relevant. The functioning of the blood vessel system often depends on the pattern of
the vessel network. Clinical images, such as from dermoscopy, might be linked via artificial intelligence to various pathologies. At the top right,
computational methods of pharmacokinetics and pharmacodynamics relate drug dose to the concentration in blood plasma and then to the mode
of action. The upper half of the figure pronounce the statistical significance; the bottom half of the figure shows models, which pronounce the
importance of physical and mechanistic dependencies. In conclusion, a direct correlation between in vitro and in vivo data might be
straight-forward, but might be also too simplistic. The laborious indirect way with step-wise experimental and computational extension of
knowledge might be harder and more expensive, but more insightful in the long term and can enrich meaningful model development
Models of melanoma transcriptomics
The melanoma transcriptome is more context-specific
than the genome and easier to measure than the pro-
teome. The pattern changes can be used to stratify
patients or to identify drug targets. Beyond this, they can
give an impression of the re-wiring of pathways. Barter
et al. applied three different strategies (single genes, gene
sets, and network analysis) to 47 melanoma microarray
datasets. They concluded, that network methods do not
perform better overall, that these different approaches
tend not to classify patients consistently, and that the
optimal method might have to be identified patient-
specifically [31]. Wang et al. performed 45 siRNA screens
of the melanoma cell line A375, whole-genome sequenc-
ing, and Bayesian gene network interference to enable
directional and synergistic conclusions. Similar to Barter’s
findings, the network hubs alone were not sufficient to
better stratify patients. However, if the network hubs are
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Table 1 Data bases containing melanoma data
Databases Information Last update Source
Melanoma Molecular Map Information about single molecules molecular 2015 [23]
Project profiles and molecular pathways involved in
melanoma progression
MelGene 83,343 CM cases and 187,809 controls and reported 2016 [24, 174]
on 1,114 polymorphisms in 280 different genes
MelanomaDB Published melanoma genomic datasets 20 May 2013 [25]
including clinical and molecular information
Melanoma Gene Database Relationship between melanoma protein-coding 02 Nov 2016 [26]
genes, microRNAs and lncRNAs
contextualized with cell-cycle and deoxyribonucleic acid
(DNA)-repair function, the prediction of an individual
prognosis was shown to be possible [32].
The concept of pathway re-wiring is based on the
following reasoning. Some mutations can cause protein
structure modifications, which in turn can alter the link-
age between proteins without changing cellular protein
levels. Two proteins only interact if the transcript level
change of one protein correlates or anti-correlates with
the transcript level change of another protein. If co-
expression is abrogated, the network connectivity reduces.
When two unrelated proteins show a new co-expression in
the next progression stage, the connectivity increases, and
a pathway re-wiring can be assumed. This network analy-
sis can be performed independent of significantly changed
differential expression and fold changes.
Kaushik et al. followed this strategy and meta-analyzed
632 melanoma microarray samples with melanoma pro-
gression stages: normal skin, non-metastatic (radial and
vertical growth phase), metastatic, and lymph node
metastases [33]. They diversified the clinical relevant
groups by pooling the data of tissue samples with
untreated and cisplatin-treated melanoma cell lines and
melanocytes. The extracted re-wired pathway hubs were
subsequently checked for drugability, which is important
as many promising targets cannot be influenced pharma-
cologically [34].
Models of melanoma proteomics
The proteome directly mirrors cellular function. Genomic
and transcriptomic data can only indirectly show the
post-transcriptional, translational, and further epigenetic
changes and are thus limited in their representation
of final physical processes. Proteomic data are, e.g.,
very beneficial for modeling signal transduction path-
ways such as the MAPK or phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)
pathway [35]. In the context of melanoma, most stud-
ies aim either at understanding resistance mechanisms
or at the response rates to particular compounds. For
example, it was possible to predict the degree of apop-
tosis for 11 melanoma cell lines treated with TRAIL
and dacarbazine (DTIC) with high accuracy. This was
achieved by grouping measurements in pathway-inspired
functional groups and using these in multivariate sta-
tistical analysis [36]. Resistance in melanoma cell lines
was studied with data-driven modeling and multivariate
statistics. 21 phosphoproteins were measured over time
in a panel of 10 cell lines subjected to different doses
of five different RAF/MAP2K inhibitors [37]. This led
to the identification of an early down-regulation of the
mitogen-activated protein kinase 8 (MAPK8)1/jun proto-
oncogene, AP-1 transcription factor subunit (JUN) path-
way upon RAF/MAP2K inhibition, but an up-regulation
in six cell lines at later time points. This study showed
that a fraction of treated cells become quiescent and
apoptosis-resistant. The same group further validated
these results and suggested targeting MAPK8, protein
tyrosine kinase 2 (PTK2), or SRC proto-oncogene, non-
receptor tyrosine kinase (SRC) to inhibit this particular
drug-resistant phenotype [38]. Bernardo-Faura et al. used
Fuzzy Logic to investigate the temporal network re-wiring
in A375 cells in response to different kinase inhibitors
[39]. The authors used a prior-knowledge network to sim-
ulate the behavior of the cells over time, and detected
discrepancies at specific time-points between the model
predictions and the measurements. This work, as well,
underlines the importance of the MAPK8 pathway in
early drug-induced changes in signaling pathways. Del
Mistro et al. studied the signaling network changes in
phospho-proteomic data due to underlying resistance of
BRAF mutated melanoma cell lines to sublethal doses
of tumor necrosis factor related apoptosis inducing lig-
and (TRAIL) receptor-targeted agonist IZI1551. Systemic
network analysis with Dynamic Bayesian modeling iden-
tified X-linked inhibitor of apoptosis (XIAP) and NF-
κB inhibitor alpha (IκBα) as potential drug targets.
Consequently, targeting these nodes in the subsequent
1Also known as c-Jun N-terminal kinases JNK
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experimental validation led to a sensitization of cells [40].
Another comprehensive study contained 89 perturbation
conditions and 143 proteomic/phenotypic measurements
with the result that bHLH transcription factor (c-Myc)
might be a potential therapeutic co-target in addition to
BRAF or MEK inhibition [41].
Models of melanomametabolomics
The metabolic state is the consequence of proteomic
function and environmental conditions such as nutri-
ent and oxygen shortages. Metabolite concentrations
can be obtained with robust measurements, and well-
established methods are available [42]. Notably, Scott
et al. used metabolic flux analysis to characterize the
response of seven melanoma cell lines to hypoxia [43].
They showed the crucial roles of both Warburg and Pas-
teur effects in melanoma and paved the way for the ther-
apeutic targeting of metabolism. While the Pasteur effect
describes reduced glycolysis with increased oxygen, the
Warburg effect refers to cancer cells performing glycol-
ysis despite the presence of oxygen [44]. Future studies
might further combine metabolic modeling with other
omics-data.
Mechanistic network models of melanoma
Completely validated mechanistic network models of
melanoma have not been published yet, but a valid
Boolean model of melanogenesis combines both ker-
atinocyte and melanocyte signaling without cancer prop-
erties. Lee et al., thereby, imposed increasing ultravi-
olet B (UVB) light intensity and modeled the cellular
response to it. The simulated profiles of the protein levels
were individually compared to literature to check qualita-
tive plausibility. Lee et al. demonstrated the central role
of catenin beta 1 (CTNNB1) in the regulation of both
melanogenesis and apoptosis. This prediction was then
validated using UVB-exposed reconstituted human skin
equivalents [45].
Moreover, a system of ordinary differential equations
(ODE) was used to model the MAPK, PIK3CA/AKT ser-
ine/threonine kinase 1 (AKT1), and other pathways with
48 species and 48 biochemical reactions [46]. The model
was an extension of themodel of PC-12 (rat adrenal gland)
cells [47] and showed that increasing dabrafenib concen-
trations cause declining pERK levels but in unphysiolog-
ical ranges. Future ODE-based modeling of melanoma
signaling would ideally improve the balance between
model size and melanoma-specific data to enable robust
predictions. Sensitivity analyses and a model selection
procedure might help to suggest key mechanisms and
intervention strategies.
As described in this section, the network informa-
tion can be used to stratify patients, to find druggable
targets, and to understand the impact of therapy on
the biochemical pathways. The next section describes
models to inter-connect cells instead of molecules.
Cell population models are used to find coherencies
between cell culture and clinical patient populations
or to understand the immune system at the whole-
body level.
Cell populationmodels: bridging cell culture to
clinics
Melanoma cells are not isolated entities but interact with
keratinocytes, fibroblasts, and immune cells. Moreover,
melanoma cells might be divided into subtypes or phe-
notypes. Population models often describe the interaction
between them, e.g., how the level of one cell population
influences the abundance of another cell population. A
subset of these models integrate cell culture data; another
subset of these models are experimentally adjusted with
human or murine in vivo data.
Melanomamodels can mimic the interplay of cell types
Flach et al. studied the interplay of melanoma cells, stro-
mal fibroblasts, and stromal fibronectin. In their interpre-
tation, free melanoma cells at the lesion border activate
fibroblasts to get mechanical support. The mechanically
supported cells proliferate until they become blocked due
to space limitations, albeit the space limitation is sim-
plified to state values in this ODE network model [48].
Accordingly, several studies point to the crucial role of
remodeling, fibronectin, and PTK2 signaling in driving
resistance to BRAF inhibitors [49, 50]. This conceptual
model of Flach et al. has been refined, validated, and
extended to BRAFi and PTK2i therapy [51]. The results
allowed a deeper understanding of the role of stroma
during acquired resistance and its potential role during
targeted therapy in drug-resistant patients [48, 51]. The
same group worked on a dynamic autophagy model with
AKT1i therapy for melanoma [52]. Integration of cell cul-
ture and clinical patient data into the autophagy model
enabled the identification of key stratification parameters.
Stratification parameters could either accompany clinical
trials or might support treatment selection in the future.
Another melanoma cell population model is provided by
Sun et al. with an excellent description of the parame-
ter origin. The considered cell types are BRAFi sensitive,
BRAFi resistant, and may or may not enter the metastatic
state after drug treatment. Cells grow until a maximum
cell burden. The set of stochastic differential equations
with 19 parameters is experimentally adjusted via cir-
culating tumor cell DNA and melanoma cell line data.
Progression-free survival is set equal with the melanoma
cell concentration for simplicity [53], whereby more data
might allow amore clinical relevant linkage between these
two. Future models with integrated pharmacokinetic ele-
ments might consider clinically relevant pharmacokinetic
models [54].
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Cell interplay is studied for melanoma immunology
Cell population models of the interplay of melanoma cells
with immune cells are helpful as melanoma is a highly
immunogenic tumor [55]. This high immunogenicity is
the reason for the success of therapies based on immune
activation in this tumor type. Indeed, melanoma was
the first cancer type for which an immune checkpoint
inhibitor and an oncolytic virus were approved [56, 57]. As
such, several computational models have been specially
developed to study the interplay between immune and
melanoma cells. For example, several ODE systems were
devised to model melanoma with Th1 and Th2 helper
lymphocytes [58], with natural killer cells (NK) in the con-
text of interleukin 21 (IL21) therapy [59], with M1 andM2
macrophages [60], or both macrophages and helper lym-
phocytes [61]. Also, vaccine strategies based on dendritic
cell therapy for melanoma were modeled with a multi-
compartment ODE system to define adequate doses and
schedules [62]. However, one drawback of these models
is that the patients’ intrinsic variables, key determinants
in immune-related therapies, were not taken into account
[63]. One study took into account the genetic signatures
being associated with resistance to immunotherapies. The
parameterized ODE model suggested co-adjuvants for
successful vaccine therapies [64]. In another study, Pap-
palardo et al. implemented an on-grid cellular automaton
model of melanoma, in which melanoma cells interact
with macrophages, T cells, and dendritic cells at differ-
ent cellular states. Pappalardo et al. highlighted the role
of TNF receptor superfamily member 9 (TNFRSF9) for
successful therapy and adjusted their model with experi-
mental data of activated or resting OT1 T-cells and anti-
TNFRSF9 antibodies in B16melanoma inmice [65]. Given
the size of the model, additional experimental data would
further improve model parameterization and robustness
[66].
In summary, cell-population models can combine clin-
ical and cell culture data and might support the determi-
nation of an individualized drug regimen based on cellular
dynamics. While these models are suitable for freely act-
ing cells, tumors are frequently restricted by the ECM and
anatomic space limitations. These effects were simplified
by three models mentioned above [48, 51, 65]. While one
refers to threedimensional (3D) spheroid growth in colla-
gen gel, two refer to tumor size in mice. Tumor growth is
more complex and requires spatial, mechanical, and phys-
iological characteristics being addressed in the following
three sections.
Spatial models of melanoma
The spatial tumor expansion in tissue has played a
subsidiary role heretofore. In the following, spatially
distributed factors of lesions and environment will be
addressed. For instance, spatial patterns in dermoscopic
pictures can be used to classify a particular lesion to
obtain hints for prospective growth and the necessity
of surgical intervention. Subsequently, combining cell-
population models with geometry provide insights into
the success of surgical therapy. When focussing on the
cellular level, the positioning and shape of cells can hint
to mechanical and thus biochemical factors, which stimu-
late local cell mass expansion. However, a more in-depth
insight into histological features of skin and other host tis-
sues indicate that solely geometrical solutions may not be
sufficient as mechanical cues significantly impact defor-
mation and development.
Pattern recognition of melanoma
The pattern of naevi andmelanoma in situ are the physical
consequence of biochemical processes in the epidermis
and are usually assessed and classified in dermatology to
initiate early therapy. The related patterns can be mod-
eled in two dimensions using a mixture theory model
[67]. The study shows how different patterns of malig-
nant cells can form within a healthy cell environment.
two-dimensional (2D) patterns of naevi and melanoma
can also be subjected to planar linear transformations
using two subsequent dermoscopic pictures. Those pic-
tures allow the classification of melanoma growth rates
and naevi symmetry [68]. The ABCD criteria for asym-
metry, border irregularity, color variation, and diameter of
melanoma have been mathematically considered too [69].
Automated optical classification of naevi and
melanomas is a fast-growing field and employs machine
learning methods for image recognition. The sensitiv-
ity and specificity of these models coincided with the
decision quality of dermatologists [70–72]. Specific
features in 2D dermoscopic images can also be used to
determine the Breslow depth with specificity and sensi-
tivity of almost 100%, which has direct prognostic value
[73]. Furthermore, the depth of invasion is an important
prognostic marker for patient survival, and the Breslow
index can be determined manually or automatically from
histopathological images [71, 74].
Models of surgical treatment
Surgical treatment is the best option for early iden-
tified melanomas. However, wide excision of pri-
mary melanoma can have counter-intuitive ramifications
according to the reaction-diffusion model of Eikenberry
et al.. The surgical resection of primary melanomas might
include tumor-associated immune cells, which lead to an
accelerated outgrowth of local metastasis due to reduced
immune suppression [75]. Computational models are
also used to assist image-guided and computer-assisted
surgery, mainly for the brain [76]. The brain, besides lung
and lymph nodes, is a preferred host tissue for metastatic
melanoma [77].
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Dissecting parameters in spatial models is a challenge
Fully experimentally validated models of melanoma
expansion are still limited to data based on 2D cell
culture experiments. In a series of reports, Treloar
et al. used a lattice cellular automaton model and an
experimental approach to identify different parameters of
colony growth, where cell motility, cell–to–cell adhesion,
and cell proliferation influenced the same: the expan-
sion of the cell colony [78, 79]. These parameters were
also estimated using a Bayesian framework coupled with
a stochastic model of 2D melanoma growth [80]. Using
melanoma and fibroblast monocultures as well as differ-
ent co-culture systems, Haridas et al. have parameter-
ized a partial differential equations (PDE) model of the
interactions of cancer cells and fibroblasts [81]. Continu-
ous modeling of melanoma cells under different osmotic
pressures was performed with a 2D lattice model to
simulate scratch assays [82]. The aim was to differenti-
ate migration/invasion between primary and metastatic
cells. New vertex modeling strategies [83] and scratch
assay analysis tools [84] might further improve this
approach.
Spatial organization of skin and confined spaces
The previously described spatial parameter determination
strategy for cell lines is especially helpful for the epider-
mal skin layer. However, the skin is more complex and
also contains irregular fibrous tissue beneath the epider-
mal layer separated by a collagenous basement membrane
[85]. At the dermal-epidermal junction, keratinocytes are
generated and stratify through the epidermis up to the
skin surface, where they keratinize to form the protective
barrier called stratum corneum. The epidermal layer is
also the most common location for melanoma initiation.
Residing melanocytes can become benign neoplasms and
appear as innate or acquired naevi [77]. Further changes
and appearing atypical cells constitute the first malig-
nant stage: the radial growth phase. From the clinical
perspective and the perspective of modeling, the base-
mentmembrane is crucial. Invasion through the basement
membrane indicates the vertical growth phase, which may
require adjuvant therapy besides surgical treatment. Phar-
macological therapy is implicated for metastatic growth
into secondary tissues. In contrast to the epidermis, the
dermis layer is streaked with collagen and elastin fibers
synthesized by fibroblasts [86], and these ECM fibers
restrict tumor expansion [87].
Using colony growth in 2D cell culture experiments
does not lead to quantitative parameters for spatial models
representing stromal processes. For example, migration
velocity depends on the ECM fiber geometry [88], the
migration process is fundamentally different in confined
structures [89], and depends on the paxillin (PXN) and
transforming growth factor beta 1 induced transcript 1
(TGFB1I1) balance related to PTK2 [90]. Moreover, BRAF
inhibition promotes matrix metalloproteinases (MMP)
activity and cell migration in three dimensions [91].
A consequent experimental parameterization of realis-
tic melanoma growth models is difficult to find and is
aggravated by the diversity of parameter origins and their
mutual dependency, as shown by Treloar et al. [78, 79].
The modeling of the tumor microenvironment has to
consider additional factors like extracellular matrix stiff-
ness and topography, oxygen and nutrients gradients, and
interstitial fluid pressure [92].
Mechanical models of melanoma
Mechanical cues in the environment directly influence
important biochemical cancer pathways and have a com-
plex impact on tumour progression [93, 94]. Conse-
quently, mechanical models get more attention and three
methods will be presented in the following: mixture the-
ory, the thermodynamically constrained averaging theory
(TCAT), and the discrete ansatz with cross-linked elastic
cells. These three methodologies can mimic the growth in
tissues, while a tissue without any malignant contortions
is already a complex modelling task [95]. As the inte-
gration and measurement of mechanical cues is not yet
widely used, a summary of experimental methods is given
below.
Impact of mechanoregulation
In three dimensions, additional factors impair drug sen-
sitivity [49, 96] and either increase or decrease the
tumor growth rate [97]. The stromal environment causes
non-genetic phenotype switches between proliferative
and mesenchymal stages [98, 99], and environmental
melanoma-associated fibroblasts are known to play an
essential role in melanoma progression [100]. Fibrob-
last activity is closely linked to ECM and thus biome-
chanics, which is now recognized as a central pillar of
tumor progression and metastasis [93, 94]. Mechanical
melanoma models consider the growth-induced defor-
mation of the ECM rich environment. The more the
proliferating mass expands, the more counterforce is gen-
erated by the connected ECM fibers. The elastic energy
is conserved and geometry dependent [87]. The mechani-
cal deformation of tissues and mechanical stress influence
intracellular signaling by mechano-sensors like PTK2
[101] or YY1 associated protein 1 (YY1AP1)/tafazzin
(TAZ) [102], which are discussed as one drug resistance
mechanism for BRAF-mutant melanoma cells [38, 49,
103] or progression marker for cutaneous and G pro-
tein subunit alpha q (GNAQ) mutant uveal melanoma
[104–106]. Proximity to mechano-regulating fibroblasts
can induce pathway changes to PIK3CA/mechanistic tar-
get of rapamycin kinase (MTOR) and switch the pheno-
type of melanoma cells to the mesenchymal state [107].
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Consequently, melanoma cells reduce the inherent stiff-
ness to facilitate invasion [108, 109]. However, our knowl-
edge of mechanosensitive pathways is far from com-
plete [109–112], and comprehension of mechanical phe-
nomenons require computational models. Additionally,
the skin, being the primary site for cutaneous melanoma,
is a mechano-sensitive organ. Skin can grow when it
is stretched, and rete ridges, projections of the epider-
mis into the dermis, were recently suspected to form
according to mechanical characteristics [86]. The skin has
inspired many computational models describing dermal
transport processes as well as providing a mechanical
understanding of the skin’s optical, functional, and struc-
tural characteristics [113].
Mixture theory
Two mixture theory models exist. One describes the
skin surface, and one mimics the vertical section [67,
114]. Balois et al. consider interstitial fluid pressure, a
mechanically optimal cell density, and friction between
the melanocytic lesion and the surrounding tissue. Ciar-
letta et al. represent melanoma in the radial growth phase
in the ECM free epidermis as a viscous fluid sliding on
a basement membrane with friction dependent growth
velocity. In a second step, this friction is neglected and
instead considered between the basement membrane and
an additional keratinocyte representing fluid. Melanoma
cell and keratinocyte fluid are adjacent to each other, and
the tumor front between them is a moving interface/ free
boundary problem subjected to stability analysis [114].
TCAT theory
TCAT models [115] represent a multi-phase approach,
which is different from the mixture theory and circum-
vents the free boundary problem. TCAT models do not
have a defined tumor boundary at the macro-scale, but
the ECM spans the whole tissue, with a higher concen-
tration at the basement membrane. The interstitial fluid,
the healthy, and the malignant cells squeeze via local rules
through the solid but deformable porous ECM network.
Averaging of local properties causes a macroscale behav-
ior that resembles the distortion of the tissue and the
invasion of the basement membrane. By adjusting the
cancer cell plasticity but not ECM integrity, the model
changes from solid to invasive growth [116].
Disordered lattice model
The discrete model [117] describes individual cells on a
2D disordered lattice. Cells are represented as spheres,
which are connected via breakable springs. The springs
mimic ECM and cell-cell contacts. Melanoma induced
MMP activity is modeled by a higher probability of
spring breaking near melanoma cells. Despite the simple
mechanical and geometrical laws, the simulation results
give a realistic impression. Because discrete models are
more computationally demanding than continuous mod-
els, they allow only limited upscaling. However, the ben-
efit of this single-cell modeling approach is the potential
discrimination between compressive and tensile stress,
which can differ strongly across the ECM biopolymer
types [118] and tumor locations [87]. The model by Taloni
et al. was validated with 2D experiments. The exper-
iments were performed under osmotic pressure with-
out fibronectin, which is an important linker between
mechanics and intracellular signaling.
Experimental methods for mechanical melanomamodels
Although modeling promises to become more and
more important in melanoma research, and continuous
improvement of the computational power make more
complex and realistic models accessible, experimentally
validated parameterization remains a crucial bottleneck.
To produce high-quality mathematical models, quanti-
tative data under standardized operating procedures are
required [119, 120]. Tumor spheres and spheroids in gen-
eral [121], and organotypic in vitro models of melanoma
[122] in particular offer more realistic experimental con-
ditions. Fully functional organotypic skin constructs [123]
can mimic all melanoma progression stages. 3D con-
structs do not only serve as carrier of cells; theymodify the
experimental outcome. Thus, quantification of hydrogel
system parameters, such as the shear or Young’s modu-
lus becomes standard. The shear modulus G of the gel
system, or the roughly three times higher Young’s modu-
lus E, is stated with the unit kPa (E=2G(1+ν); ν: Poisson’s
ratio) [49, 101, 111]. Knowing the impact of mechani-
cal cues in the modeling process prevents common data
integration problems. For example, the frequently used
matrigel for invasion assays has an elastic modulus of
0.45 kPa and is consequently a weaker barrier than the
basement membrane reaching 250-500 kPa [124, 125].
Additionally, the impact of stress relaxation should be
not underestimated as it has a decisive impact on fur-
ther development [126]. A range of hydrogel systems is
available [127] and can also be used for automated drug
testing [128] albeit questions of standardisation of 3D cell
culture models remain to be addressed [129]. Mechani-
cal parameters are difficult to measure and span up to 5
log steps depending on tissue moisture and experimen-
tal setting [130]. Experimental mechano-sensors enable
the measurement of sub-molecular force transmissions
[131], and fluorescent oil microdroplets allow the mea-
surement of anisotropic stress fields in 3D tissues [132].
Tunable alginate microcapsules can be used to deter-
mine the mechanical growth-pressure of spheroids [133],
and high throughput mechanical testing of cells is possi-
ble with optical deformation of cells [134]. If the direct
measurement of stiffness is not possible, the lamin A/C
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(LMNA) to lamin B1/2 (LMNB1/2) ratio serves as an
appropriate biomarker of stiffness sensing [135]. The clin-
ical imaging technology elastography gives direct access to
the tissue stiffness fields and thus tumor locations in vivo
[136]. Elastography can also be used for the in vivo stag-
ing of melanoma [137]. The integration of elastography
and melanoma mechano-signaling could highlight stiff
areas where mechano-sensors influence melanoma signal
transduction. This could facilitate the translation of these
research models into clinically relevant predictive models.
The complexity of the interaction of tumor cells with their
environment requires a step-wise understanding with a
multitude of experimental techniques [138] and related
computational efforts (Fig. 1). Computational scientists
must incorporate the experimental context to develop
meaningful computational melanoma progression mod-
els.
Transport of oxygen and drugs
Several models describe how oxygen and drugs are trans-
ported from the source to a melanocytic lesion as the
presence of oxygen and nutrients control the viability of
cancerous and healthy tissues. For melanoma, multiple
oxygen sources as well as vascular and pericellular trans-
port routes influence tumour progression as described in
the following.
Oxygenation of melanoma in skin and brain
Impaired oxygen and nutrient delivery cause necrotic
cores, which is a widespread assumption. A necrotic core
can be modelled explicitly [115] or indirectly via nutrient
concentration reduction [114]. However, Thibaut Balois &
Martine Ben Amar questioned the existence of necrotic
cores in epidermal melanoma and took the atmospheric
oxygen source into account [67, 139]. If oxygen came only
from the dermal vasculature, the oxygen partial pressure
would drop to around eight mmHg at the skin surface
[140]. Mild hypoxic conditions are present around the
basement membrane, promoting melanocyte prolifera-
tion [141] as well as melanoma progression [142]. Inter-
estingly, the brain, a common location for metastasized
melanoma, has also a low tissue oxygen concentrations
reaching 35 mmHg [143].
Experimental aspects of oxygen
Most established melanoma cell lines are cultured under
atmospheric oxygen and are therefore evolutionarily
adjusted to these artificial conditions. Molecular oxygen
sensors for 3D settings [144] are as possible as advanced
hypoxia sensors [145] to improve the validation of com-
putational models. Oxygen consumption rates of cells
can be obtained with the Seahorse technology [146] and
were determined for melanocytes andmelanoma cell lines
[147].
Models of melanoma-associated vascularization
The tumor-associated vascularization is influenced by
oxygen limitations and mechanical cues [148, 149]. Math-
ematical blood vessel models define an independent com-
putational research field [150]. Notably,Welter and Rieger
combined the discrete modeling of vasculature remod-
eling with the continuous gradients of melanoma cells,
oxygen, nutrients, and drugs [151]. They used melanoma-
specific data for the vasculature [152]. Thismodel is useful
to simulate blood flow and to study the impact of space
limitations on simple drug diffusion and nutrient supply.
Wang et al. created an agent-based model containing both
melanoma and endothelial cells with a focus on angio-
genesis. They tested the combined effect of doxorubicin
chemotherapy and kinase insert domain receptor (KDR)2
inhibition with sunitinib [153]. It might be interesting to
see a follow-up model with improved use of biological
data for parameter, synergy, and validation. Dzwinel et
al. coupled several continuous sub-models of melanoma
growth to increase modeling quality and efficiency. They
used a single phase continuum for growth accompa-
nied by angiogenesis, vascular remodeling, and tumor
ECM interactions. The model was embedded in a realis-
tic virtual skin structure, and the melanoma progression
resembled nodular, lentigo maligna, and acral lentiginous
melanoma [154]. The same group extended the model by
a discrete vascularization dynamic, which was coupled
intermittently [155]. The used approach, called “super-
modeling” by the authors, is a theory on model syn-
chronization [156]. However, the connection coefficients
seem untrained in comparison to non-biological appli-
cation areas, and the coupling remains weak [156]. This
modeling group is very active in melanoma, refines the
model continuously, and also uses particle automata mod-
els to produce visually realistic models [157, 158]. Taken
together, while these models provide valuable insight
into the vasculature, much work is needed to ensure
adequate melanoma-specific parametrizations and valida-
tions. Einar Rofstads’ group provides excellent data sets
on melanoma-associated vascularization and might be
considered for further modeling projects [159].
Drug delivery models
Blood vessels are an essential route for drugs to the loca-
tion of action, and pharmacokinetics is studied to deter-
mine the drug concentration in local blood plasma. How-
ever, the transport from the blood vessels or skin surface
to the melanoma cells depends on the diffusion coefficient
of the microanatomical structure. Drug delivery models
are available for both the penetration of spherical tumors
with melanin-binding antibodies for radioimmunother-
apy [160] and SPACE-EGF mediated transdermal delivery
2Also known as vascular endothelial growth factor receptor 2 (VEGFR)
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of siRNA against the MYC proto-oncogene, bHLH tran-
scription factor (MYC) [161]. However, the impact of
biomechanics and tumor physiology on drug delivery is
not considered by those models but discussed for MU89
melanoma in mice [162, 163]. A proliferating mass makes
fibrous tissue crowded and compressed. This might lead
to a reduced interstitial fluid volume fraction and thus
impaired drug transport. Such a phenomenon might be
best modeled with the multi-phase flow in porous media
[115].
Discussion
The generation of a mechanistic and predictive model
is a serious and work-intensive endeavor that forces all
participants to think deeper [9]. Ultimately, the reward
is more aim-tailored research but also the discovery of
hidden causalities, which would otherwise have rendered
explorative research inconclusive or contradictory. Recent
progress in devising experimental procedures for param-
eter determination has fueled the work of several com-
putational groups. Conversely, certain phenomena can
only be understood with computational methods, such
as computational mechanics. Mathematical modeling of
melanoma presents several specificities ranging from the
high mutation load and cell plasticity to oxygen uptake
at the skin surface. Nevertheless, most of the current
models of melanoma are not yet sufficiently adapted to
the requirements in biology and medicine. The recurring
problems in almost all reviewed research can be expressed
in four challenges and are discussed accordingly.
First challenge: tumor heterogenity
The first challenge is the cellular heterogeneity. The high
mutation load, signaling network plasticity, and cell line
heterogeneity makes the fitting of mechanistic ODE sys-
tems or straightforward network inference from patients’
biopsies difficult. Instead, most studies focus on well-
characterized cell line collections to carefully extract spe-
cific regulatory network motifs with multivariate statis-
tics. The cell line-specific models are suitable for under-
standing drug responses. Notable works used systems
biology to investigate the impact of new compounds such
as TRAIL [36, 40], while others focus on identifying
potential targets by perturbing the biological system with
several kinase inhibitors [37, 39].
Second challenge: melanoma type specifity
The second challenge is melanoma type specific model-
ing. Melanocytic tumors occur in various forms at differ-
ent locations and are based on different etiologies [164].
A few important types are lentigo maligna melanoma,
superficial spreading melanoma, and acral lentiginous
melanoma. Nonetheless, computational papers often refer
to a general term of melanoma, albeit each melanoma
type can substantially differ in treatment response, envi-
ronmental setting, and growth pattern. In computa-
tional biology, mechanistic links between growth patterns
and melanoma-type specific biochemical markers could
prospectively reach the same importance as in pathology
[77, 164]. Instead of constructing models around a few
abstract mathematical parameters and retrospectively
allocate histopathological sections to a given simulation
outcome, modelers might emphasize the pathological
causality and relevant biochemical root-causes leading
to a melanoma-type specific growth outcome. A deeper
examination of cancer pathology, anatomy, and physiology
might also prevent unjustified assumptions. Some authors
set initial lesions at positions, where they rarely occur,
such as the epidermal stratum corneum, albeit the stra-
tum basale is often the location of initial lesions [164]. The
unique oxygen patterns in skin [139, 140], the tendency of
melanocytes to proliferate better in mild hypoxic condi-
tions [141], the strong oxygen consumption of melanoma
cells [147] as well as the importance of driver mutations
in this highly mutated cancer type [15, 16] are further
factors, which might find more consideration by mod-
elers of melanoma. Not all concepts, model structures,
and parameters can be taken from models of other can-
cer types. Future melanomamodels might represent more
melanoma type specific characteristics and parameters,
whereby attention should also be drawn to the respective
histopathology and the host tissue in which the simulated
melanoma is intended to be simulated. Eventually, context
and tissue-specific modeling of certain melanoma types is
more insightful than generic cancer or melanoma models.
Third challenge: complexity
The third challenge is the appropriate level of complex-
ity as neither very small and simple nor extensive models
can deliver reliable predictions. Models that are as sim-
ple as possible are the gold standard in modeling, as
shown by Kim or Picco et al. [51, 52]. However, if mod-
els neglect major effects, or the remainingmodel elements
are too abstract to be interpreted, the result will be of
little use. For example, careful work was performed to
determine mutually dependent parameters of a cell colony
[81]. However, the impact of the mechanical environ-
ment on these parameter values [94], such as migra-
tion [88], exacerbates the transfer of these parameters
to complex 3D models. On the contrary, especially large
scale models which have been set-up [46, 153] will ben-
efit from sufficient and appropriate melanoma-specific
data, to further increase the validity of their conclu-
sions. The same can be observed in physical oncology.
Mixture theory allows easier models and fewer param-
eters. Still, it is difficult to measure abstract parame-
ters or to biologically interpret the equations as they
pool too many biological sub-systems to homogeneous
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entities. In contrast, Sciumé et al. accurately differentiates
between cells, fibrous compounds, and interstitial fluid.
This makes experimental parameter determination eas-
ier and aligns better with medical and biological lines
of thinking. However, the model requires many parame-
ters, which must still be biologically validated. Best inter-
disciplinary communication is reached with agent-based
models, were cells are separately depicted. However, the
computational demand for simulating individual cells is
substantial. More experience is necessary to find the right
level of complexity that can be of practical use and allow
both computationally feasible and biologically sound
models.
Fourth challenge: correct data integration
The fourth challenge is the accurate integration of evi-
dence. Experimental facts and assumed fiction are diffi-
cult to distinguish in many publications, and it is of little
use if an extensive biological section is written indepen-
dently of the computational part but is hardly reflected
by the equations at the end [114]. To enable scrutiny by
melanoma experts and to facilitate evidence-based model
extensions or improvements, it seems necessary that each
element of a model structure is biologically explained,
interpreted, and referenced only within the degree of fac-
tual implementation, even if this requires extensive sup-
plemental information. The reasoning behind modeling
decisions should be accountable. At least, the behavior
of all system elements should be tested for plausibil-
ity as done in one work [45]. Besides the verifiability
of the model structure, parameters are very ambiguous
in most papers, and only a few papers provided supple-
mental information about data extraction and conversion
[53]. Unfortunately, many publications work with uncu-
rated parameter lists, and interested readers are recom-
mended to trace back parameter values to the primary
source to judge the validity. We found that data indi-
cated as melanoma-specific were based on other diseases
and tissue origins such as glioblastoma or the adrenal
gland. Estimated or assumed parameters were often refer-
enced in subsequent papers as if they were experimentally
determined values. Moreover, the context of experimen-
tal origin often do not fit the intended model context, or
whole parameter sets are normalized in an original paper
and then carried over several computational paper gen-
erations regardless of biology studied. In order to bring
models closer to biological evidence, parameters should
be referenced only to the original experimental publica-
tions, and information should be given on the experimen-
tal context and potential parameter conversions. Not all
required data are available, but transparency on evidence
is generally lacking. It remains to be debated to which
extend a model must contain melanoma-specific data to
be considered a melanoma model or how close a model
must match medical evidence to be seen as a valuable
contribution to melanoma research.
Lack of interdisciplinary is the root cause
These four challenges reflect the most persistent problem
of melanoma-specific modeling: interdisciplinarity. Com-
putational models require close collaboration between
experimental, clinical, and computational scientists in
an iterative procedure. Modeling generates hypotheses,
which have to be tested in vitro, and experimental
results must inform the design of better models and
allow the falsification of theories [165]. However, a gen-
eral problem in the interdisciplinary work in biology
and medicine is that the more demanding the nec-
essary mathematical and physical framework becomes,
the more disconnected it becomes from the experi-
mental and theoretical knowledge in biology, medicine,
and pharmacology. On the one hand, computational
groups cannot reproduce and test the diverse parame-
ter sources in their labs, lacking the time and expertise
to embrace the whole complexity of biological relation-
ships and experimental methods. On the other hand,
biologists and clinicians find it difficult to help, as the
more developed computational procedures are likewise
difficult to comprehend. Therefore, better quality stan-
dards between and in both computational [166] and
biomedical research [167] need to be developed and
adopted. A more sophisticated way might be the step-
wise model development accompanied by advanced cell
culture strategies (Fig. 1). The gap between the differ-
ent disciplines is not closed yet, which leads to concep-
tual problems in the models and inappropriate parameter
choices.
Conclusion
Cancer is a highly complex, heterogeneous disease, char-
acterized by a series of genetic, metabolic, and functional
changes at the cellular and tissue level [168]. Melanoma-
specific dynamics during tumor progression stages in
both plasticity [108] and genetics [169] highlight the
need for integrative models to better understand disease
mechanisms of melanoma. The model-building commu-
nity works across different scales and comprises studies
centered on signaling pathways and gene regulation [22],
metabolism [42, 170], epithelial tissue mechanics [171],
tumor physiology [172], and the immune system [173],
respectively. Four challenges for computational melanoma
models have been discussed:
• Melanoma heterogeneity,
• Melanoma-type specificity,
• The balance between simplicity and thoroughness,
and
• Melanoma data integration and evidence.
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Consequently, interdisciplinarity and clinical relevance
remain a challenge regarding the practical use of
melanoma-specific systems biology and physical oncol-
ogymodels. However, if all disciplines improve interaction
and collaboration, the future promises us an unmatched
insight.
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